Eylea Injection Treatment

Eylea Injection contains Aflibercept, a recombinant fusion protein that acts as a VEGF inhibitor. It is administered intravitreal (directly into the eye) to treat retinal conditions that cause abnormal blood vessel growth and fluid leakage, leading to vision loss.

• Eylea is approved for managing:
• Wet Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)
• Diabetic Retinopathy (DR)
• Macular Edema following Retinal Vein Occlusion (RVO)
• Retinopathy of Prematurity (ROP) in infants

It works by binding to VEGF-A and PlGF, preventing them from stimulating unwanted blood vessel formation. Treatment typically begins with monthly injections, followed by maintenance doses every 2 months, depending on the condition and response.